
What did the FDA just approve for myasthenia gravis — and who is Klygefa actually for?
The FDA has approved Klygefa (gefurulimab), from Alexion, AstraZeneca Rare Disease, for adults with generalised myasthenia gravis who are anti-AChR antibody positive. It is the first dual-binding nanobody C5 inhibitor approved in the US, given as a once-weekly self-injection; the PREVAIL Phase III trial showed a statistically significant MG-ADL improvement over placebo at week 26. A prescription treatment for one specific diagnosed condition — not a cure.
Short answer: on November 16, 2026, the FDA approved Klygefa (gefurulimab), from Alexion — AstraZeneca’s rare-disease arm — for adults with generalised myasthenia gravis whose disease is anti-AChR antibody positive. AstraZeneca says it is the first and only dual-binding nanobody C5 inhibitor approved in the US, and it is taken as a once-weekly injection patients give themselves under the skin using an autoinjector.Why it matters: myasthenia gravis is an autoimmune disease in which antibodies disrupt the signal between nerves and muscles, causing weakness that worsens with use. Blocking complement protein C5 is an established way to reduce that attack.
In the PREVAIL Phase III trial, published in JAMA Neurology, patients on Klygefa improved more than patients on placebo on the MG-ADL scale — a measure of daily activities such as talking, chewing and breathing — at week 26 (treatment difference −1.6 points, p<0.0001), with improvement reported from the first week and sustained through one year.Read it plainly: this is a prescription treatment for one specific, diagnosed form of the disease — anti-AChR antibody-positive generalised myasthenia gravis in adults. It is not a cure, and it is not a treatment for muscle weakness in general. Like other C5 inhibitors, it carries a boxed warning for serious meningococcal infections, so vaccination requirements apply.
Whether it fits a particular patient is a decision for that patient and their neurologist — this card is general information, not medical advice.
Ask AI about this tip
Send this tip to your favorite AI assistant for a plain-language walkthrough, follow-up questions, or help applying it to your device.